GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Net Income

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Net Income : $-18.84 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Telomir Pharmaceuticals's Net Income for the three months ended in Mar. 2024 was $-6.26 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-18.84 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Telomir Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.23.


Telomir Pharmaceuticals Net Income Historical Data

The historical data trend for Telomir Pharmaceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Net Income Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Net Income
-0.14 -0.85 -13.07

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Get a 7-Day Free Trial Premium Member Only -0.48 -1.55 -1.71 -9.33 -6.26

Telomir Pharmaceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Telomir Pharmaceuticals's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-13.072+0+0+0
=-13.07

Telomir Pharmaceuticals's Net Income for the quarter that ended in Mar. 2024 is calculated as

Net Income(Q: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-6.255+0+0+0
=-6.26

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telomir Pharmaceuticals  (NAS:TELO) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Telomir Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Telomir Pharmaceuticals Net Income Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines